Maple Comprehensive research overview of NAD+ biology, biosynthetic pathways, age-related decline mechanisms, and precursor supplementation research. All information is drawn from peer-reviewed literature for research reference only.
Molecular Profile
| Full Name | Nicotinamide Adenine Dinucleotide (oxidized form) |
|---|---|
| Abbreviation | NAD+ (oxidized); NADH (reduced) |
| Molecular Formula | C21H27N7O14P2 |
| Molecular Weight | 663.43 g/mol |
| CAS Number | 53-84-9 |
| Classification | Dinucleotide coenzyme |
| Endogenous | Yes, present in all living cells |
| Key Biosynthetic Enzyme | NAMPT (nicotinamide phosphoribosyltransferase) |
| Research Status | Active preclinical and clinical investigation of precursor supplementation |
Biological Significance and Core Functions
NAD+ is one of the most abundant and functionally versatile molecules in eukaryotic cells. It participates in over 500 enzymatic reactions and serves two fundamentally distinct roles: as a redox coenzyme shuttling electrons in metabolic reactions (glycolysis, TCA cycle, oxidative phosphorylation, fatty acid oxidation), and as a consumed substrate for signaling enzymes including sirtuins, PARPs, and CD38/CD157 ectoenzymes (Imai & Guarente, 2014; DOI: 10.1016/j.tcb.2014.04.002).
The distinction between these two roles is critical for understanding NAD+ biology: in redox reactions, NAD+ is recycled (reduced to NADH and back), so total dinucleotide pools are conserved. In signaling reactions, NAD+ is cleaved and consumed, requiring continuous biosynthesis to maintain cellular pools.
Sirtuin-Dependent Deacetylation
Sirtuins (SIRT1-7) are NAD+-dependent deacylases that regulate metabolism, circadian rhythm, DNA repair, inflammation, and mitochondrial biogenesis. Each sirtuin reaction consumes one molecule of NAD+, producing nicotinamide, O-acetyl-ADP-ribose, and the deacetylated substrate. SIRT1 and SIRT3 are particularly sensitive to NAD+ fluctuations, with SIRT3 governing mitochondrial protein acetylation and metabolic flexibility (Verdin, 2015; DOI: 10.1126/science.aac4854).
PARP-Mediated DNA Repair
Poly(ADP-ribose) polymerases, particularly PARP1, detect DNA strand breaks and catalyze poly(ADP-ribosyl)ation (PARylation) using NAD+ as the ADP-ribose donor. PARP1 is the largest single consumer of cellular NAD+ during genotoxic stress, and its activity directly competes with sirtuins for the available NAD+ pool. This competition has significant implications: under conditions of chronic DNA damage, PARP hyperactivation can deplete NAD+ sufficiently to impair sirtuin-dependent metabolic regulation (Alemasova & Lavrik, 2019; DOI: 10.1093/nar/gkz120).
Wilk et al. (2020) demonstrated that reduced intracellular NAD+ suppressed recruitment of the DNA repair protein XRCC1 to sites of genomic damage, and that NAD+ or NMN supplementation restored repair capacity independently of CD73 activity (DOI: 10.1038/s41598-020-57506-9).
CD38 and NAD+ Consumption
CD38 is an ectoenzyme and the dominant NADase in mammalian tissues. Camacho-Pereira et al. (2016) demonstrated that CD38 expression and activity increase with aging, and that CD38 is required for age-related NAD+ decline. In CD38 knockout mice, NAD+ levels were preserved during aging and mitochondrial function was maintained through a SIRT3-dependent mechanism. Critically, the study also identified CD38 as the main enzyme degrading the NAD+ precursor NMN in vivo, suggesting CD38 modulates the efficacy of precursor supplementation strategies (DOI: 10.1016/j.cmet.2016.05.006).
NAD+ Biosynthetic Pathways
Mammalian cells maintain NAD+ pools through three distinct biosynthetic routes:
The enzyme NAMPT is rate-limiting for the salvage pathway and is regulated by circadian clock machinery, creating diurnal oscillations in NAD+ levels that couple metabolism to the light-dark cycle (Imai & Guarente, 2014).
Age-Related NAD+ Decline
Multiple studies have documented tissue-specific NAD+ decline during aging across model organisms. Verdin (2015) reviewed evidence showing that NAD+ levels fall in brain, liver, muscle, adipose tissue, and skin during aging in rodent models. The mechanisms driving this decline are multifactorial and not fully resolved, but involve:
Increased CD38 expression: CD38 activity rises with age and chronic inflammation, accelerating NAD+ degradation. CD38 knockout fully prevents age-related NAD+ decline in mice (Camacho-Pereira et al., 2016).
Chronic PARP activation: Accumulated DNA damage with age increases PARP1 activity, consuming more NAD+.
Decreased NAMPT expression: The rate-limiting salvage enzyme declines in some tissues with age, reducing NAD+ recycling capacity.
Inflammatory signaling: Senescence-associated secretory phenotype (SASP) factors upregulate CD38 on immune and endothelial cells, creating a feed-forward loop of NAD+ depletion and inflammation.
NAD+ Precursors: NMN and NR
Two NAD+ intermediates have dominated preclinical and early clinical research: nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR). Yoshino, Baur, & Imai (2018) reviewed the biology and therapeutic potential of both precursors, noting that while both elevate tissue NAD+ levels, their pharmacokinetics, tissue distribution, and metabolic fates differ substantially (DOI: 10.1016/j.cmet.2017.11.002).
| Parameter | NMN | NR | NAD+ (direct) |
|---|---|---|---|
| Full Name | Nicotinamide mononucleotide | Nicotinamide riboside | Nicotinamide adenine dinucleotide |
| Molecular Weight | 334.22 g/mol | 255.25 g/mol | 663.43 g/mol |
| Pathway Entry | Direct substrate for NMNAT enzymes | Phosphorylated to NMN by NRK1/NRK2 | Direct cofactor (requires cellular uptake) |
| Cellular Uptake | Slc12a8 transporter (tissue-specific); also dephosphorylated to NR extracellularly | Equilibrative nucleoside transporters | Poorly membrane-permeable; may require ectoenzyme processing |
| Preclinical NAD+ Elevation | Demonstrated in liver, muscle, brain, heart, adipose | Demonstrated in liver, muscle, brain, brown adipose | Demonstrated via IV/IP routes; oral bioavailability limited |
| Key Limitation | Susceptible to CD38-mediated degradation in vivo | Rapidly metabolized in gut to NAM before absorption | Large molecule, poor oral bioavailability |
SARM1 and the NMN Safety Question
Loreto et al. (2023) raised an important research consideration: the pro-degenerative enzyme SARM1 is activated by NMN binding. In the context of axonal biology, failure to convert NMN to NAD+ (due to loss of NMNAT2) leads to NMN accumulation, SARM1 activation, and programmed axon degeneration. This creates a theoretical tension with NMN supplementation strategies. The authors noted that while no adverse axonal effects have been reported in NMN supplementation studies to date, the question of whether supraphysiological NMN levels could engage SARM1 under specific conditions remains open (DOI: 10.1016/j.neures.2023.01.004).
Clinical Translation Status
Iqbal & Nakagawa (2024) reviewed the gap between preclinical promise and clinical outcomes for NAD+ precursors. While supplementation with NMN and NR reliably elevates blood and tissue NAD+ levels in human subjects, clinical efficacy for specific disease endpoints has been limited compared to animal models. The review highlighted the emerging role of gut microbiota in modulating oral NAD+ precursor metabolism, noting that orally administered NR and NMN interact extensively with intestinal microbiome before systemic absorption (DOI: 10.1016/j.bbrc.2024.149590).
Navas & Carnero (2021) reviewed the broader NAD+ landscape, including its roles in cancer metabolism, stemness, and immune function, emphasizing that NAD+ biology intersects with multiple disease contexts beyond aging (DOI: 10.1038/s41392-020-00354-w).
Research Product Specifications
Maple Research Labs NAD+
Purity verified via third-party HPLC and mass spectrometry analysis
Supplied as lyophilized powder for reconstitution in research settings
Batch-specific Certificate of Analysis available upon request
Storage: -20°C recommended; protect from light and moisture
Key Research Citations
| Citation | Focus | DOI |
|---|---|---|
| Imai & Guarente, 2014 | NAD+ and sirtuins in aging and disease (review) | 10.1016/j.tcb.2014.04.002 |
| Verdin, 2015 | NAD+ in aging, metabolism, neurodegeneration | 10.1126/science.aac4854 |
| Camacho-Pereira et al., 2016 | CD38 drives age-related NAD+ decline via SIRT3 | 10.1016/j.cmet.2016.05.006 |
| Yoshino, Baur & Imai, 2018 | NMN and NR biology and therapeutic potential | 10.1016/j.cmet.2017.11.002 |
| Alemasova & Lavrik, 2019 | PARP1 PARylation mechanism and regulation | 10.1093/nar/gkz120 |
| Wilk et al., 2020 | NAD+ enhances PARP-dependent DNA repair | 10.1038/s41598-020-57506-9 |
| Navas & Carnero, 2021 | NAD+ in metabolism, stemness, immunity, cancer | 10.1038/s41392-020-00354-w |
| Loreto et al., 2023 | NMN/SARM1 intersection and safety considerations | 10.1016/j.neures.2023.01.004 |
| Migaud, Ziegler & Baur, 2024 | Challenges in targeting NAD+ metabolism (Nat Rev MCB) | 10.1038/s41580-024-00752-w |
| Iqbal & Nakagawa, 2024 | NAD+ precursors in age-related diseases, gut microbiota | 10.1016/j.bbrc.2024.149590 |
Related Research Pages
MOTS-c Mitochondrial Peptide | NAD+ and MOTS-c both converge on AMPK-dependent metabolic regulation
Peptide Purity Testing Methods | How HPLC and mass spectrometry verify compound identity and purity
Evaluating Research Suppliers | Framework for assessing COA transparency and analytical rigor
Frequently Asked Questions
What is NAD+ and why is it important in research?
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in all living cells that participates in over 500 enzymatic reactions. It serves as both a redox carrier in core metabolic pathways (glycolysis, TCA cycle, oxidative phosphorylation) and as a consumed substrate for signaling enzymes including sirtuins (SIRT1-7), PARPs, and CD38. Research interest has intensified because NAD+ levels decline with age in multiple tissues, and this decline is associated with metabolic dysfunction, impaired DNA repair, and mitochondrial deterioration in preclinical models.
What causes NAD+ levels to decline with age?
Age-related NAD+ decline is driven by multiple converging mechanisms: increased expression and activity of the NADase CD38 (shown by Camacho-Pereira et al. to be necessary and sufficient for age-related NAD+ decline in mice), chronic PARP1 hyperactivation from accumulated DNA damage, reduced expression of the salvage pathway enzyme NAMPT, and inflammatory signaling that upregulates CD38 on immune cells. These mechanisms create a feed-forward loop where declining NAD+ impairs the very processes (DNA repair, anti-inflammatory signaling) that would slow further decline.
What is the difference between NMN, NR, and NAD+ as research compounds?
NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are biosynthetic precursors that cells convert to NAD+ through different enzymatic steps. NMN is a direct substrate for NMNAT enzymes, while NR must first be phosphorylated by NRK1/NRK2 kinases to become NMN. NAD+ itself is a larger molecule (663 Da) with limited membrane permeability when administered exogenously. Each has different pharmacokinetic profiles, tissue distribution patterns, and metabolic fates that are still under active investigation. The choice of compound depends on the specific research question and experimental system.
Where can I buy NAD+ for research in Canada?
Maple Research Labs supplies NAD+ as a research reagent within Canada, with third-party purity verification via HPLC and mass spectrometry. All products include batch-specific Certificates of Analysis and ship same-day from Canadian facilities. NAD+ is supplied for in-vitro and preclinical research use only and is not intended for human consumption or therapeutic application.
How should NAD+ be stored for research use?
NAD+ should be stored as lyophilized powder at -20°C, protected from light and moisture. Once reconstituted, NAD+ solutions should be aliquoted and stored at -20°C to minimize degradation. Avoid repeated freeze-thaw cycles. NAD+ is hygroscopic and photosensitive, so working solutions should be prepared fresh when possible and protected from direct light exposure during experiments.